Description: H.Amdt.233 — 109th Congress (2005-2006)
As of 12/18/2013 the description for this amendment has not been received.
An amendment to insert a new section providing authority for the Secretary to require that the manufacturer of an approved drug conduct one or more studies to confirm or refute an empirical or theoretical hypothesis of a significant safety issue with the drug.
House Amendment Code:
House Tally Clerks use this code to manage amendment information.